Crown Laboratories To Buy Revance For $3.10/Share In Amended And Restated Merger Deal

(RTTNews) - Crown Laboratories, Inc. on Monday announced an amended and restated agreement to acquire all outstanding shares of Revance Therapeutics, Inc. (RVNC) for $3.10 per share in cash.

The new deal comes in response to several developments with Revance, such as its settlement with Teoxane for alleged breach of distribution agreement, its prospects as a standalone company, and its recent commercial performance relative to prior 2024 financial guidance.

Following the transaction, which is expected to be completed in the first quarter of 2025, Revance's stock will be delisted on the Nasdaq.

Currently, Revance's stock is falling 20.39 percent, to $3.04 on the Nasdaq.